Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)
Status:
Active, not recruiting
Trial end date:
2020-08-15
Target enrollment:
Participant gender:
Summary
Double blinded randomized clinical trial designed to evaluate the security and efficacy of
hydroxychloroquine as treatment for COVID-19 severe respiratory disease. The investigators
hypothesize that a 400mg per day dose of hydroxychloroquine for 10 days will reduce all-cause
hospital mortality in patients with severe respiratory COVID-19 disease.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Respiratory Diseases, Mexico